Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections

Microbiology and Immunology

Volumn 57, Issue 7, 2013, Pages 527-535

  Günther, Georg ^a   Dreger, Bettina ^b  

^a Medical Care Center for Blood and Cancer Diseases   (Germany)

^b Deutschland GmbH   (Germany)

Author keywords

Chronic lymphocytic leukemia; Intravenous immunoglobulin; Recurrent infections; Secondary immunodeficiency

Indexed keywords

IMMUNOGLOBULIN;

ADULT; ADVERSE OUTCOME; AGED; ARTHRALGIA; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL TOLERANCE; INCIDENCE; INFECTION RATE; MALE; NAUSEA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PRURITUS; RECURRENT INFECTION; RETROSPECTIVE STUDY; SHIVERING; TREATMENT DURATION;

CHRONIC LYMPHOCYTIC LEUKEMIA; INTRAVENOUS IMMUNOGLOBULIN; RECURRENT INFECTIONS; SECONDARY IMMUNODEFICIENCY;

ADULT; AGED; BACTERIAL INFECTIONS; COHORT STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INCIDENCE; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RECURRENCE; TREATMENT OUTCOME;

EID: 84880404637     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/1348-0421.12060     Document Type: Article

References (28)

1. Catovsky D., Richards S., Matutes E., Oscier D., Dyer M.J., Bezares R.F., Pettitt A.R., Hamblin T., Milligan D.W., Child J.A., Hamilton M.S., Dearden C.E., Smith A.G., Bosanquet A.G., Davis Z., Brito-Babapulle V., Else M., Wade R., Hillmen P. (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370: 230-239.
2. Eichhorst B.F., Busch R., Hopfinger G., Pasold R., Hensel M., Steinbrecher C., Siehl S., Jager U., Bergmann M., Stilgenbauer S., Schweighofer C., Wendtner C.M., Dohner H., Brittinger G., Emmerich B., Hallek M. (2006) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107: 885-891.
3. Sutton L., Chevret S., Tournilhac O., Divine M., Leblond V., Corront B., Lepretre S., Eghbali H., Van Den Neste E., Michallet M., Maloisel F., Bouabdallah K., Decaudin D., Berthou C., Brice P., Gonzalez H., Chapiro E., Radford-Weiss I., Leporrier N., Maloum K., Nguyen-Khac F., Davi F., Lejeune J., Merle-Beral H., Leporrier M. (2011) Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood 117: 6109-6119.
4. Tsai C.Y., Ray A.S., Tumas D.B., Keating M.J., Reiser H., Plunkett W. (2009) Targeting DNA repair in chronic lymphocytic leukemia cells with a novel acyclic nucleotide analogue, GS-9219. Clin Cancer Res 15: 3760-3769.
5. Rai K.R. (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46: 219-234.
6. Attard A.R., Thomas G.D., Bradwell A.R. (1992). The use of intravenous immunoglobulin in malignant disorders. In: Yap P. L. ed. Clinical Applications of Intravenous Immunoglobulin Therapy. Edinburgh: Churchill Livingstone.
7. Jurlander J., Geisler C.H., Hansen M.M. (1994) Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. Eur J Haematol 53: 114-118.
8. The European Agency for the Evaluation of Medicinal Products. (2010) Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) (EMA/CHMP/BPWP/94038/2007 rev. 3).
9. Besa E.C. (1984) Use of intravenous immunoglobulin in chronic lymphocytic leukemia. Am J Med 76: 209-218.
10. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. (1988) Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med 319: 902-907.
11. Ehninger G., Jopski B., Dopfer R., Wahn U., Grehen J., Zurborn K.H., (1994) Efficacy and safety of pasteurized intravenous 7S-immunoglobulin in primary and secondary immune deficiencies: results of a multicenter trial. 12th European Immunology Meeting Barcelona Abstract W50-15: 457.
12. Boughton B., Jackson N., Lim S., Smith N. (1995) Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haem 17: 75-780.
13. Chapel H.M., Lee M. (1992) Immunoglobulin replacement in patients with chronic lymphocytic leukemia (CLL): kinetics of immunoglobulin metabolism. J Clin Immunol 12: 17-20.
14. Gamm H., Huber Ch., Chapel H., Lee M., Ries F., Dicato M.A. (1994) Intravenous immune globulin in chronic lymphocytic leukaemia. Clin Exp Immunol (Suppl 1): 17-20.
15. Molica S., Musto P., Chiurazzi F., Specchia G., Brugiatelli M., Cicoira L., Levato D., Nobile F., Carotenuto M., Liso V., Rotoli B. (1996) Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 81: 121-126.
16. Carbone P.P., Kaplan H.S., Musshoff K., Smithers D.W., Tubiana M. (1971) Report of the Committee on Hodgkin's disease staging classification. Cancer Res 31: 1860-1861.
17. Durie B.G., Salmon S.E. (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36: 842-854.
18. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., Hillmen P., Keating M.J., Montserrat E., Rai K.R., Kipps T.J. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446-5456.
19. Instituto Grifols S.A. Flebogamma 5%: Summary of product characteristics available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000781/WC500023473.pdf. Last accessed: October 29, 2012.
20. The European Agency for the Evaluation of Medicinal Products. (1999) Notice to Marketing Authorisation Holders. Pharmacovigilance Guidelines. CPMP/PhVWP/108/99.
21. Herold G. (2010). Internal Medicine. Cologne, Germany: Gerd Herold, Lulu. com.
22. Kratz A., Ferraro M., Sluss P.M., Lewandrowski K.B. (1993) Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. N Engl J Med 351: 1548-63.
23. Jolles S., Sewell W.A., Misbah S.A. (2005) Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 142: 1-11.
24. Matamoros N., De Gracis J., Hernandez F., Pons J., Alvarez A., Jimenez V. (2005) A prospective controlled crossover trial of a new presentation (10% vs. 5%) of a heat-treated intravenous immunoglobulin. Int Immunopharmacol 5: 619-626.
25. Cabanillas F., Liboy I., Pavia O., Rivera E. (2006) High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol 17: 1424-1427.
26. US FDA. Guidance for Industry. Efficacy and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary immune deficiency. Last accessed: October 29, 2012. FDA 29-6-0008; Available from URL: http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm078526.pdf.
27. Hooper J.A. (2008) Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am 28: 765-778 viii.
28. Berger M., Pinciaro P.J. (2004) Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 24: 389-396.